Remarks :
After I completion of my intermediate (intermediate state of Andhra Pradesh), I wrote the entrance test of ap emcee, & I got a rank 32000 in ap emcet, and finally, we got a notification from the intermediate board of Andhra Pradesh to apply for counseling for your higher studies, then I apply for counseling and complete the certificate verification process and got a notification of allotment of a seat of PharmD course in qis college Ongole and then we admitted in qis college onwards 12/10/2018 with the report card.
Course Curriculum Overview :
I have my dream to become a drug inspector so I chose this course and faculty are friendly to everyone and teaching skills are very impressive, the student ratio is good & faculty qualification is Ph.D., there is no difficulty in passing exams because we won the course as our passion so no difficulty.
Internships Opportunities :
Pharmacovigilance and software side for codings like NCBI and research centers in Delhi and the united states. Projects on various departments like in this pandemic there is a vaccination monitoring program and having a departmental review and adverse drug reactions monitoring and preventing.
Placement Experience :
From 5th year students eligible for campus placements, reddy laboratory, allopathy, ayurvedic there are a lot of offers for pharmacy students, the highest average package is 4.5 lakhs per annum percentage about 70 and plans after getting a lot of opportunities like duty doctors pharmacovigilance, coding.
Loan/ Scholarship Provisions :
There is a government scholarship JAGAN ANNA VIDYA DEVEENA & JAGAN ANNA VASATHI DEVEENA for all minorities and backward classes & eligible students if sc and st students have a scholarship from central and state.
Campus Life :
Qis college festival this may b conduct in the month of November & December, there is a lot of reference books like pharmacovigilance, about sports all sports should b willing for students and have a separate couch, there is a student-run social group are "united of pharmacy".
Comments